Immune Thrombocytopenia – First Line Management

Author: Dr. Ali Eshaghpour

Reviewer: Dr. Rick Ikesaka

Objectives:

At the end of the self-assessment module, participants will be able to:

1. Describe the first-line management of patients with ITP without bleeding.
2. Describe the first-line management of patients with ITP with bleeding.
3. Explain the rationale for the sequencing of second-line agents in the management of patients with ITP who do not respond to first-line therapies.
4. Describe common side effects of rituximab

CHS Scientific Planning Committee Members (2021-22)

Dr. Joanne Britto – Resident Physician, Hematology-Oncology
Dr. Yan Xu – Fellow Physician, Hematology
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflicts of Interest: None